
Intuitive Surgical (ISRG) Stock Forecast & Price Target
Intuitive Surgical (ISRG) Analyst Ratings
Bulls say
Intuitive Surgical has demonstrated robust growth with a 14% increase in Ion utilization and a 35% surge in SP utilization, reflecting strong demand and a growing installed base. The company's Da Vinci system utilization has improved by approximately 2% year-over-year, showcasing the benefits of the new D5 system and strong procedure growth despite typical seasonal fluctuations. Additionally, Intuitive Surgical has raised its gross margin guidance to 67-67.5%, driven by higher system placements and an improved tariff outlook, which indicates a positive trajectory for the company's financial performance.
Bears say
Intuitive Surgical's revenue from services fell slightly short of expectations at $396 million, indicating potential challenges in sustaining growth amid macroeconomic uncertainties affecting hospital capital budgets and robotic system purchases. The company continues to experience market resistance towards robotic surgical approaches, particularly in newer markets, alongside a prolonged rollout of next-generation systems and pressures on procedure volumes, particularly in bariatric surgery. Furthermore, external factors such as tariffs on imports from Mexico and the impact of third-party instrument reprocessing on consumable average selling prices contribute to an overall negative outlook for Intuitive Surgical's stock performance.
This aggregate rating is based on analysts' research of Intuitive Surgical and is not a guaranteed prediction by Public.com or investment advice.
Intuitive Surgical (ISRG) Analyst Forecast & Price Prediction
Start investing in Intuitive Surgical (ISRG)
Order type
Buy in
Order amount
Est. shares
0 shares